Janus Henderson portfolio manager Daniel Lyons said biotech’s recent weakness appeared driven by deleveraging and technical factors rather than deteriorating fundamentals. He said Democrats may prioritize healthcare coverage stability and defend existing drug-price provisions, while he does not expect new drug-pricing legislation.
Lyons said the November 5 selloff in biotech reflected broader deleveraging and technical factors, rather than weaker fundamentals. He said declines were sharpest among genomics, diagnostics and life-science tools companies that had benefited from AI enthusiasm and increasingly stretched valuations, while some traditional biotech companies continued to trade at attractive valuations.
Lyons said biotech had emerged from the post-pandemic drawdown and 2022-2023 rate-hike cycle as a healthier, more disciplined sector, with stronger balance sheets, more experienced management and more commercial-stage assets. He said Democrats could focus on expanding access and protecting coverage, including restoring Affordable Care Act subsidies and protecting existing Medicaid coverage. Lyons expects Democrats to defend existing Medicare drug-price negotiation and other Inflation Reduction Act affordability provisions rather than pursue new drug-pricing legislation.
